Role of clopidogrel and etoricoxib in obesity complications induced by monosodium glutamate in male rats

Muhammed M. Al-Ani; Huda F. Hasan

doi:10.53730/ijhs.v6nS1.6065

Authors

Muhammed M. Al-Ani Department of Pharmacology and Toxicology, College of Pharmacy, University of Anbar
Huda F. Hasan
dr.hudaalqaraghuli@yahoo.com
Department of Physiology, Biochemistry and Pharmacology, College of Veterinary Medicine, University of Baghdad

Keywords:

Clopidogrel, Etoricoxib, obesity, mono sodium glutamate

Abstract

This study aimed to estimate therapeutic role of clopidogrel and etoricoxib against cardiovascular changes in rats induced obese by Monosodium Glutamate (MSG). The experiment was performed in 30 rats divided into five groups as C-: negative control group, C+: positive control group (MSG 4mg/g),T1: received clopidogrel at dose 10.97 mg/kg, T2: received etoricoxib at dose 8.48 mg/kg and T3: received combination of clopidogrel and etoricoxib at dose 5.04 and 4.03 mg/kg respectively, then BW, BMI, TG, leptin, adiponectin, troponin-l and histopathology for heart and adipose tissue were measured, depending on results of current study the conclusion that can be drawn is there are a good role of both etoricoxib and clopidogrel alone and in combination therapy by succeeded in protection from obesity complications that induced by MSG.

Downloads

Download data is not yet available.

References

Knight, J.A.J.A.o.C. and L. Science, Diseases and disorders associated with excess body weight. 2011. 41(2): p. 107-121.

Zalesin, K.C., et al., Impact of obesity on cardiovascular disease. 2008. 37(3): p. 663-684.

Ranjani, H., et al., Epidemiology of childhood overweight & obesity in India: A systematic review. 2016. 143(2): p. 160.

Lawrence, M., et al., Public health nutrition and sustainability. 2015. 18(13): p. 2287-2292.

He, K., et al., Association of monosodium glutamate intake with overweight in Chinese adults: the INTERMAP Study. 2008. 16(8): p. 1875-1880.

Williams, C.L., et al., Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. 2002. 106(1): p. 143-160.

Kabir, F., et al., Etoricoxib treatment prevented body weight gain and ameliorated oxidative stress in the liver of high-fat diet–fed rats. 2021. 394(1): p. 33-47.

Karaźniewicz-Łada, M., D. Danielak, and F.J.E.o.o.p. Główka, Genetic and non-genetic factors affecting the response to clopidogrel therapy. 2012. 13(5): p. 663-683.

Cunha, N., et al., Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats. 2010. 87(11-12): p. 375-381.

Hata, K., et al., Monosodium glutamate-induced diabetic mice are susceptible to azoxymethane-induced colon tumorigenesis. 2012. 33(3): p. 702-707.

Luna, L.G., Manual of histologic staining methods of the Armed Forces Institute of Pathology. 1968.

Schneider, C.A., W.S. Rasband, and K.W.J.N.m. Eliceiri, NIH Image to ImageJ: 25 years of image analysis. 2012. 9(7): p. 671-675.

Westphal, S.A.J.C.c., Obesity, abdominal obesity, and insulin resistance. 2008. 9(1): p. 23-31.

Von Diemen, V., E.N. Trindade, and M.R.M.J.A.C.B. Trindade, Experimental model to induce obesity in rats. 2006. 21: p. 425-429.

Collison, K.S., et al., Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. 2009. 50(8): p. 1521-1537.

Wang, J.H., et al., Fasting adiponectin is inversely correlated with metabolic syndrome in patients with coronary artery disease. Intern Med, 2010. 49(8): p. 739-47.

Kingsley, O., et al., The effect of monosodium glutamate (MSG) on the gross weight of the heart of albino rats. 2013. 1(2).

Bojanic, V., et al., Diltiazem prevention of monosodium glutamate toxicity on hypothalamus in Wistar rats. 2004. 12(suppl 1): p. 19-20.

Farombi, E., O.J.H. Onyema, and e. toxicology, Monosodium glutamate-induced oxidative damage and genotoxicity in the rat: modulatory role of vitamin C, vitamin E and quercetin. 2006. 25(5): p. 251-259.

Hadi, N.R., et al., Antiatherosclerotic potential of clopidogrel: antioxidant and anti-inflammatory approaches. 2013. 2013.

Heim, C., et al., Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts. 2015. 47(1): p. 180-187.

Doğan, A., et al., Effect of obesity and serum leptin level on clopidogrel resistance. 2016.

Jiang, L.P., et al., Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice. 2021.

Chopra, V., et al., The role of clopidogrel in the management of patients with ischemic heart disease. 2003. 17(5): p. 467-477.

Ekor, M., et al., Celecoxib exhibits therapeutic potential in experimental model of hyperlipidaemia. 2021. 16(8): p. e0247735.

Yapca, O.E., et al., Benefits of the antioxidant and anti‐inflammatory activity of etoricoxib in the prevention of ovarian ischemia/reperfusion injury induced experimentally in rats. 2014. 40(6): p. 1674-1679.

Takemoto, J.K., et al., Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. 2008. 47(11): p. 703-720.

De Vecchis, R., et al., Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. 2014. 62(6): p. 437-448.

Lagathu, C., et al., Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. 2003. 311(2): p. 372-379.